Metformin will celebrate 50 years of clinical use in 2007. Pioglitazone was introduced into clinical practice in 1999. Both metformin and pioglitazone have positive effects on components of the metabolic syndrome, namely: insulin resistance, hyperinsulinaemia, visceral obesity, hyperglycaemia, dyslipidaemia and hypertension and risk factors involved in endothelial dysfunction, inflammation and atherosclerosis. Improvements in cardiovascular outcomes have been demonstrated in patients at high risk of macrovascular events with pioglitazone (PROactive) and in overweight patients with metformin (UKPDS 34). Pioglitazone may also help to sustain beta-cell function. Introduction of combination therapy using two differently acting oral antidiabetic agents at the time of diagnosis or early thereafter is becoming increasingly common in order to reach glycaemic targets (e.g. HbA1C ≤7.0%). The combination of metformin and pioglitazone in an early stage of type 2 diabetes enables greater likelihood that these targets can be with insulin secretagogues. attained without the risk of hypoglycaemia associated with insulin secretagogues
Kahn SEThe relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia2003; 46:3-19.
2.
Campbell IWPioglitazone - an oral antidiabetic agent and metabolic syndrome modulator . Can theory translate into practice? Br J Diabetes Vasc Dis2005;5:209-16.
3.
Klein R.Hyperglycemia and microvascular and macrovascular disease in diabetes . Diabetes Care1995;18:258-68.
4.
Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ2000;321:405-12.
5.
Goodarzi MO, Bryer-Ash M.Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obes Metab2005;7:654-65.
6.
UK Prospective Diabetes Study (UKPDS) Group.Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet1998;352:854-65.
7.
Avandia Summary of Product Characteristics.2005. 8. ACTOS Summary of Product Characteristics . 2005.
8.
Bailey CJ, Feher MDTherapies for diabetes including oral agents and insulins. Birmingham: Sherborne Gibbs Limited, 2004.
9.
Natali A., Ferrannini E.Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia2006;49: 434-41.
10.
Bailey CJBiguanides and NIDDM. Diabetes Care1992;15:755-72.
11.
Cusi K., DeFronzo RAMetformin: a review of its metabolic effects. Diabetes Rev1998;6:89-131.
Diamant M., Heine R.Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence . Drugs2003;63:1373-405.
14.
Lebovitz HE , Banerji MAInsulin resistance and its treatment with thiazolidinediones. Rec Prog Horm Res2001 ;58:265-94.
15.
Tan MH, Baksi A., Krahulec B. et al. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care2005;28:544-50.
16.
Charbonnel B., Schernthaner G., Brunetti P. et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes . Diabetologia2005;48:1093-104.
17.
Ovalle F., Bell DSClinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab2002;4:56-9.
18.
UK Prospective Diabetes Study (UKPDS) Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998;352:837-53.
19.
Barnett AH, O'Gara G.Diabetes and the heart. London: Churchill Livingstone, 2003.
20.
Haffner SMThe importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocr Rev1998 ;19:583-92.
21.
National Institute for Health and Clinical Excellence.Management of Type 2 diabetes: Management of blood pressure and blood lipids (Guideline H). 2002. Inherited Clinical Guideline H.
22.
Reaven GMBanting lecture1988. Role of insulin resistance in human disease. Diabetes1988;37:1595-607.
23.
Howlett HCS , Bailey CJA risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf1999 ;20:489-503.
24.
Kawamori R. , Matsuhisa M., Kinoshita J. et al. Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp-OGL Study Group. Diabetes Res Clin Pract1998;41:35-43.
25.
Herz M., Johns D., Reviriego J. et al. A randomized, double-blind, placebocontrolled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus . Clin Ther2003;25:1074-95.
26.
Rosenblatt S. , Miskin B., Glazer NB, Prince MJ, Robertson KEThe impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis2001;12:413-23.
27.
Bays H., Mandarino L., DeFronzo RARole of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab2004;89:463-78.
28.
Bailey CJTreating insulin resistance in type 2 diabetes with metformin and thiazolidinediones . Diabetes Obes Metab2005 ;7:675-91.
29.
Mayerson AB, Hundal RS, Dufour S. et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes2002;51:797-802.
30.
Miyazaki Y. , Mahankali A., Matsuda M. et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients . J Clin Endocrinol Metab2002;87:2784-91.
31.
Campbell IW , Howlett HCWorldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. Diabetes Metab Rev1995;11(suppl 1):S57-S62.
32.
Betteridge DJDiabetic dyslipidaemia: past, present and future. Pract Diab Int2004;21:78-85.
33.
Wild S., Byrne CDThe role of treatment to increase HDL-cholesterol and decrease triglyceride concentrations in prevention of coronary heart disease in Type 2 diabetes . Diabet Med2004;21(suppl 4):8-11.
34.
Ginsberg HNHypertriglyceridemia: new insights and new approaches to pharmacologic therapy. Am J Cardiol2001 ;87:1180.
35.
Chiquette E. , Ramirez G., Defronzo R.A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med2004;164:2097-104.
36.
van Wijk JP , de Koning EJ, Martens EP, Rabelink TJThiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol2003;23:1744-9.
37.
Goldberg RB , Kendall DM, Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care2005;28:1547-54.
38.
Derosa G., Gaddi AV, Piccinni MN et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. Diabetes Obes Metab2006;8:197-205.
39.
Berhanu P., Kipnes MS, Khan MA et al. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diabetes Vasc Dis Res2006;3:39-44.
40.
Dormandy JA , Charbonnel B., Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet2005;366:1279-89.
41.
Ginsberg H. , Plutzky J., Sobel BEA review of metabolic and cardiovascular effects of oral antidiabetic agents: Beyond glucose lowering . J Cardiovasc Risk1999;6:337-46.
42.
Goke B., on behalf of the German Pioglitazone Study Group.Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus. Treat Endocrinol2002;1:329-36.
43.
Pavo I., Jermendy G., Varkonyi TT et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab2003 ;88:1637-45.
44.
Yki-Jarvinen H.The PROactive study: some answers, many questions . Lancet2005;366:1241-2.
45.
Waugh J., Keating GM, Plosker GL, Easthope S., Robinson DMPioglitazone: a review of its use in type 2 diabetes mellitus. Drugs2006; 66:85-109.
46.
Home PD, Pocock SJ, Beck-Nielsen H. et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia2005;48:1726-35.
Isoda K., Young JL, Zirlik A. et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol2006;26:611-17.
49.
Trost S., Pratley R., Sobel B.Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes. Curr Diab Rep2006;6:47-54.
50.
Pfutzner A. , Marx N., Lubben G. et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol2005;45:1925-31.
51.
Szapary PO, Bloedon LT, Samaha FF et al. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol2006; 26:182-8.
52.
Shimizu H., Oh-I S., Tsuchiya T., Ohtani KI, Okada S., Mori M.Pioglitazone increases circulating adiponectin levels and subsequently reduces TNFalpha levels in Type 2 diabetic patients: a randomized study. Diabet Med2006;23:253-7.
53.
Bakris G., Viberti G., Weston WM, Heise M., Porter LE, Freed MIRosiglitazone reduces urinary albumin excretion in type II diabetes . J Hum Hypertens2003;17:7-12.
54.
Yanagawa T. , Araki A., Sasamoto K., Shirabe S., Yamanouchi T.Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes . Metabolism2004;53:353-7.
55.
Matthews DR , Cull CA, Stratton IM, Holman RR, Turner RCUKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group . Diabet Med1998;15:297-303.
56.
Buchanan TA , Xiang AH, Peters RK et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes2002; 51:2796-803.
57.
Xiang AH, Peters RK, Kjos SL et al. Effect of Pioglitazone on Pancreatic {beta}-Cell Function and Diabetes Risk in Hispanic Women With Prior Gestational Diabetes. Diabetes2006;55:517-22.
58.
Leiter LABeta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes. Diabet Med2005;22:963-72.
59.
Walter H., Lubben G.Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus. Drugs2005;65: 1-13.
60.
Gerstein HC , Yusuf S., Holman R., Bosch J., Pogue J.Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial . Diabetologia2004;47:1519-27.
